FAM166C

Across TCGA pan-cancer cohorts, FAM166C Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM166C data layer compared with 23 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher FAM166C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM166C expression acts as an unfavorable survival marker.

LGG and PRAD are the cancer types where FAM166C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.156	0.753	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FAM166C–LGG (DFS)

Open the LGG breakdown →